Elicio Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Elicio Therapeutics, Inc. (ELTX) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-17.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-03-17
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $0.00.
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2021-12-31 was -$28.00K, a 800.00% decline year-over-year.
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2021-03-31 was $55.00K.
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $4.00K, a 0.00% change from fiscal 2020.
- Elicio Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $4.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 10-K · filed 2023-03-17 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | -$28.00K derived: sum of 2 quarters · filed 2023-03-17 | ||
| 2021-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $4.00K 10-K · filed 2023-03-17 | ||
| 2021-09-30 | $32.00K 10-Q · filed 2022-11-14 | |||
| 2021-03-31 | $55.00K 10-Q · filed 2022-05-16 | $59.00K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $4.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |